Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metal-On-Metal Hip Post-market Studies Behind Schedule, NEJM Article Highlights

This article was originally published in The Gray Sheet

Executive Summary

Delays in getting FDA-ordered surveillance studies up and running for hip implants should be addressed at an advisory panel this week, researchers from the Pew Health Group and Cornell argue.

You may also be interested in...



FDA '522' Guidance: 15-Month Deadline To Comply With Postmarket Order

The agency has issued a final guidance on Sec. 522 postmarket study orders about five years after a draft version. In the interim, Congress stipulated a 15-month deadline for companies to start the FDA-mandated studies, a requirement emphasized in the new document.

Data Questions Dominate Metal-On-Metal Panel; New Monitoring Recommended

FDA advisory panel examines science behind controversial metal-on-metal hips, recommends new monitoring, possible label changes.

House Passes Compromise User Fee Bill; Senate To Vote This Week

The final bill includes device user fee reauthorization and additional FDA reforms, including a streamlined device reclassification process that has some in the device industry nervous.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031335

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel